New insider activity at ACADIA Pharmaceuticals ( (ACAD) ) has taken place on March 7, 2025.
Director Elizabeth A. Garofalo has recently sold 4,919 shares of ACADIA Pharmaceuticals stock, amounting to a total transaction value of $89,673.
Recent Updates on ACAD stock
In the last 24 hours, ACADIA Pharmaceuticals reported strong Q4 financial results, with DAYBUE and NUPLAZID sales showing significant growth. The company outlined ambitious growth plans, including expanding its DAYBUE field force in the U.S. and building a commercial team in the EU for the anticipated launch of trofinetide. Despite the positive financial performance, Citizens JMP lowered ACADIA’s price target due to revenue guidance challenges related to pricing and regulatory uncertainties. The analyst noted that while NUPLAZID continues to perform well, the broader pipeline offers multiple opportunities for long-term value. ACADIA’s strategic initiatives and strong cash position provide leverage for internal investments and potential acquisitions.
More about ACADIA Pharmaceuticals
YTD Price Performance: -3.11%
Average Trading Volume: 2,615,503
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $3.05B